CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy
July 11 2016 - 8:00AM
Business Wire
Method for pre-sensitizing cancer cells,
making them more susceptible to follow-on treatments
CEL-SCI Corporation (NYSE MKT: CVM)
announces that it has been granted a new European patent covering
its investigational Phase 3 cancer immunotherapy drug Multikine*
(Leucocyte Interleukin). The patent, EU Patent: EP 1 773 368 B1,
titled “A Method Of Pre-Sensitizing Cancer Prior To Treatment With
Radiation and/or Chemotherapy And A Novel Cytokine Mixture,” is not
limited to any one particular type of cancer and can include
multiple types of cancer.
This invention relates to a novel method for pre-sensitizing
cancer cells prior to a therapeutic treatment such as chemotherapy
or radiation therapy. This effect is created by CEL-SCI’s
immunotherapy drug Multikine which, as part of its mode of action,
induces cancerous cells to enter a proliferative cell cycle phase
therapy, thereby potentially increasing their vulnerability to
chemotherapy and radiation therapy.
Geert Kersten, Chief Executive Officer of CEL-SCI, said, “This
European patent should protect one of the largest applications for
Multikine, namely its use in combination with radiation and
chemotherapy. Our ongoing Phase 3 clinical trial in head and neck
cancer patients is administering Multikine therapy as part of a
first-line treatment, before any other treatments and prior to
surgery, followed by radiation or concurrent
chemoradiotherapy.”
About the Multikine Phase 3 Study
The Multikine Phase 3 study is enrolling patients with advanced
primary (not yet treated) squamous cell carcinoma of the head and
neck. The objective of the study is to demonstrate a statistically
significant improvement in the overall survival of enrolled
patients who are treated with the Multikine treatment regimen plus
standard of care ("SOC") vs. subjects who are treated with SOC
only. The study is being conducted in 24 countries and has enrolled
over 850 patients so far.
About Multikine
Multikine is an investigational immunotherapeutic agent that is
being tested in an open-label, randomized, controlled, global
pivotal Phase 3 clinical trial as a potential first-line treatment
for advanced primary squamous cell carcinoma of the head and neck.
Multikine is designed to be a different type of therapy in the
fight against cancer: one that appears to have the potential to
work with the body's natural immune system in the fight against
tumors.
Multikine is also being tested in a Phase 1 study under a
Cooperative Research and Development Agreement ("CRADA") with the
U.S. Naval Medical Center, San Diego, and at University of
California, San Francisco (UCSF), as a potential treatment for
peri-anal warts in HIV/HPV co-infected men and women. Dr. Joel
Palefsky, a world-renowned scientist and Key Opinion Leader (KOL)
in human papilloma virus (HPV) research and the prevention of anal
cancer, is the Principal Investigator at UCSF, which was added to
the study in July 2015.
CEL-SCI has also entered into two additional co-development
agreements for up to $3 million each with Ergomed Clinical Research
Limited to further the development of Multikine for cervical
dysplasia/neoplasia in women who are co-infected with HIV and HPV
and for peri-anal warts in men and women who are co-infected with
HIV and HPV.
About CEL-SCI Corporation
CEL-SCI's work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. Its lead
investigational therapy, Multikine (Leukocyte Interleukin,
Injection), is currently being studied in a pivotal Phase 3
clinical trial as a potential neoadjuvant treatment for patients
with squamous cell carcinoma of the head and neck. If the study
endpoint, which is a 10% improvement in overall survival of the
subjects treated with the Multikine treatment regimen plus the
current standard of care (SOC) as compared to subjects treated with
the current SOC only, is satisfied, the study results will be used
to support applications that the Company plans to submit to
regulatory agencies in order to seek commercial marketing approvals
for Multikine in major markets around the world. Additional
clinical indications for Multikine that are being investigated
include the treatment of cervical dysplasia in HIV/HPV co-infected
women, and the treatment of peri-anal warts in HIV/HPV co-infected
men and women. A Phase 1 trial of the former indication has been
completed at the University of Maryland. The latter indication is
now in a Phase 1 trial in conjunction with the U.S. Naval Medical
Center, San Diego, under a CRADA and UCSF. CEL-SCI has issued
patents on Multikine from the US, Europe, China and Japan.
CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand
Epitope Antigen Presentation System) technology for the potential
treatment of pandemic influenza in hospitalized patients and as a
potential vaccine for the treatment of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near
Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in CEL-SCI
Corporation's filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K for the year
ended September 30, 2015. The Company undertakes no obligation to
publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
*Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy have not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is currently in
progress.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160711005430/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024